Edition:
United Kingdom

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe


Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co .Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries and in Turkey. 

Related Company News

Company Quote

496.0
5.0 +1.02%
23 Jul 2019